NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage biopharmaceutical company dedicated to developing oral, non-statin therapies for patients at risk of cardiovascular disease (CVD), has announced an active participation in the 2025 American Heart Association (AHA) Scientific Sessions, occurring from November 7 to 10 in New Orleans. The company plans to present pivotal findings from its Phase 3 BROOKLYN, BROADWAY, and TANDEM trials, specifically regarding obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor.

Key presentations at the AHA will include an oral presentation on "Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles," set for November 9, delivered by John Kastelein. Additionally, a digital poster presentation titled, "Obicetrapib in combination with ezetimibe on top of atorvastatin regresses atherosclerotic plaque lesions," will be presented by Jose Inia on November 10.

Beyond the AHA sessions, NewAmsterdam management will engage in three investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 in Boston, followed by the Stifel Healthcare Conference on November 12 in New York, and concluding with the Jefferies London Healthcare Conference on November 19. Fireside chats at these events will feature Chief Executive Officer Dr. Michael Davidson and Chief Financial Officer Ian Somaiya.

NewAmsterdam's mission is to address unmet needs in LDL-C management, particularly for patients who find existing treatments inadequate. The company is focusing on the efficacy and safety of obicetrapib as a potential game-changer in LDL-C lowering therapies alongside statin treatments. Following the live presentations, recordings will be accessible on the company’s investor relations website.

As NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) approaches critical presentations at the 2025 American Heart Association (AHA) Scientific Sessions in November, investors should closely monitor developments surrounding the company's pivotal Phase 3 trials involving its lead drug candidate, obicetrapib. The results presented during the conference, particularly the pooled analysis from the BROOKLYN and BROADWAY trials, could significantly influence market sentiment and stock performance.

NewAmsterdam targets a substantial unmet need in the cardiovascular disease (CVD) space with its innovative oral CETP inhibitor. The ongoing focus on LDL cholesterol management positions obicetrapib as a potential game-changer, especially for patients who have not responded adequately to traditional therapies. The data from these trials, especially regarding safety and efficacy, will provide critical insights into the drug's therapeutic profile. A strong showing could enhance investor confidence, while any disappointments may lead to volatility.

Additionally, NewAmsterdam's participation in three investor conferences shortly after the AHA event adds another layer of engagement with the investment community. The scheduled fireside chats led by CEO Michael Davidson and CFO Ian Somaiya will offer management's perspective on the clinical data and strategic direction, providing investors with an opportunity to gauge the company's vision and operational insights.

Investors should treat this period as a pivotal moment for NewAmsterdam, as successful outcomes from the presentations could catalyze a positive price action. Analysts recommend accumulating shares ahead of these events while closely monitoring trading volumes and market reactions post-presentation. Consider setting stop-loss orders to mitigate risks associated with potential volatility following the announcements. This strategy could optimize positioning in NewAmsterdam Pharma as it seeks to redefine LDL-lowering therapies.